Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca has licensed an early-stage lipid-lowering drug from China's CSPC Pharmaceutical in a deal worth up to $2 billion, extending a run of Chinese…
AstraZeneca is buying into the hot Lp(a) race with an up-to-$2 billion licensing pact for CSPC's oral small molecule YS2302018. The deal gives AZ a potential…
PURSUIT randomized Phase 2 (n=426) of AstraZeneca's oral PCSK9 inhibitor AZD0780 (laroprovstat) showed dose-dependent LDL-C reductions with a favorable safety…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AstraZeneca entered exclusive licensing agreement with CSPC for YS2302018, an early-stage oral small molecule Lp(a) disruptor with potential combination use with AZ's AZD0780 PCSK9 inhibitor. CSPC receives $100M upfront plus up to $1.92B in development and commercial milestones and tiered royalties. Top-25 pharma buyer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. (this deal) | 2024 | $2.0B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2024 deals · AstraZeneca PLC deals · Cardiovascular deals